A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features.

Trial Profile

A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2016

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Acronyms RESOLVE-3
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Sep 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 08 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top